Renaissance Technologies LLC has recently announced that it has increased stake in Atossa Therapeutics Inc (NASDAQ:ATOS) by 15.67%. After grabbing 1.24 million shares, the institutional investor is now in possession of 0.17 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.99% having worth around $0.92 million. Moreover, GSA Capital Partners LLP increased its share by 44788.0 to have a control over 0.35 million shares.
Atossa Therapeutics Inc (ATOS) concluded trading on 12/28/23 at a closing price of $0.98, with 2.59 million shares of worth about $2.54 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.74% during that period and on Thursday the price saw a gain of about 8.17%. Currently the company’s common shares owned by public are about 126.62M shares, out of which, 125.28M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 2 times over the past 12 months. They bought 50,000 shares in 1 of the transactions. In 1 selling transactions, insiders dumped 50,000 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Atossa Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 3.78 million shares of worth totaling $2.81 million. The company recently came buying 0.0 shares which brought its stake up to 3.02% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 0.62 million shares, have now control over 0.50% of the stake in the company. It holds 0.0 shares of worth $0.46 million.
Atossa Therapeutics Inc (NASDAQ: ATOS) started trading at $0.95, above $0.05 from concluding price of the previous day. However, the stock later moved at a day high price of 1.1000, or with a gain of 8.17%. Stock saw a price change of 34.08% in past 5 days and over the past one month there was a price change of 25.49%. Year-to-date (YTD), ATOS shares are showing a performance of 84.69% which increased to 89.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.50 but also hit the highest price of $1.39 during that period. The average intraday trading volume for Atossa Therapeutics Inc shares is 303.09K. The stock is currently trading 30.01% above its 20-day simple moving average (SMA20), while that difference is up 36.45% for SMA50 and it goes to 18.99% higher than SMA200.
Renaissance Technologies LLC acquired 1.24 million shares of Atossa Therapeutics Inc having value of about $0.92 million. Data submitted at the U.S SEC by Renaissance Technologies LLC revealed that the firm now holds 0.17 million shares in the company valued at close to $164934.0, or have control over 15.67% stake in the company. Atossa Therapeutics Inc (NASDAQ: ATOS) currently have 126.62M outstanding shares and institutions hold larger chunk of about 19.33% of that. Holding of mutual funds in the company is about 5.67% while other institutional holders and individual stake holders have control over 7.26% and 0.00% of the stake respectively.
The stock has a current market capitalization of $122.31M and its 3Y-monthly beta is at 1.22. It has posted earnings per share of -$0.24 in the same period. It has Quick Ratio of 28.35 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATOS, volatility over the week remained 9.55% while standing at 6.38% over the month.
Analysts are in expectations that Atossa Therapeutics Inc (ATOS) stock would likely to be making an EPS of -$0.06 in the current quarter, while forecast for next quarter EPS is -$0.06 and it is -$0.25 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.06 which is -$0.06 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.06 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -15.87% while it is estimated to decrease by -6.85% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on January 26, 2018 offering a Buy rating for the stock and assigned a target price of $2 to it.
